Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Berk, MD
Arcutis Biotherapeutics, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
49 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Arcutis Clinical Site 41
Calgary, Alberta, Canada
- Arcutis Clinical Site 29
Fredericton, New Brunswick, Canada
- Arcutis Clinical Site 11
Markham, Ontario, Canada
- Clinical Site 25
Mississauga, Ontario, Canada
- Arcutis Clinical Site 32
Peterborough, Ontario, Canada
- Arcutis Clinical Site 09
Windsor, Ontario, Canada
- Arcutis Clinical Site 24
Montreal, Quebec, Canada
- Arcutis Clinical Site 57
Montgomery, Alabama, United States
- Arcutis Clinical Site 34
Scottsdale, Arizona, United States
- Arcutis Clinical Site 58
Little Rock, Arkansas, United States
- Arcutis Clinical Site 40
Beverly Hills, California, United States
- Arcutis Clinical Site 06
Encinitas, California, United States
- Arcutis Clinical Site 52
Los Angeles, California, United States
- Arcutis Clinical Site 05
San Diego, California, United States
- Arcutis Clinical Site 08
San Francisco, California, United States
- Arcutis Clinical Site 62
Thousand Oaks, California, United States
- Arcutis Clinical Site 30
Coral Gables, Florida, United States
- Arcutis Clinical Site 04
Jacksonville, Florida, United States
- Arcutis Clinical Site 15
Largo, Florida, United States
- Arcutis Clinical Site 39
Miami Lakes, Florida, United States
- Arcutis Clinical Site 38
North Miami Beach, Florida, United States
- Arcutis Clinical Site 01
Tampa, Florida, United States
- Arcutis Clinical Site 61
Wellington, Florida, United States
- Arcutis Clinical Site 26
Sandy Springs, Georgia, United States
- Arcutis Clinical Site 13
Rolling Meadows, Illinois, United States
- Arcutis Clinical Site 48
Clarksville, Indiana, United States
- Arcutis Clinical Site 02
Indianapolis, Indiana, United States
- Arcutis Clinical Site 03
Louisville, Kentucky, United States
- Arcutis Clinical Site 36
Rockville, Maryland, United States
- Arcutis Clinical Site 55
Auburn Hills, Michigan, United States
- Arcutis Clinical Site 54
Bay City, Michigan, United States
- Arcutis Clinical Site 46
Clarkston, Michigan, United States
- Arcutis Clinical Site 37
Detroit, Michigan, United States
- Arcutis Clinical Site 10
New Brighton, Minnesota, United States
- Arcutis Clinical Site 33
Reno, Nevada, United States
- Arcutis Clinical Site 42
East Windsor, New Jersey, United States
- Arcutis Clinical Site 17
Gresham, Oregon, United States
- Arcutis Clinical Site 14
Portland, Oregon, United States
- Arcutis Clinical Site 16
Portland, Oregon, United States
- Arcutis Clinical Site 35
Newtown Square, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 27 Jan 2021
- Primary completion
- 30 Aug 2022
- Completion
- 30 Aug 2022
- Last update posted
- 9 Oct 2024
- Registered enrollment
- 654
- Registry id
- NCT04773587
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.